USFDAAug 7, 2026, 07:07 AM
NRx Pharma FDA Review: Packaging Issue, No Drug Deficiencies
AI Summary
NRx Pharmaceuticals received feedback from the FDA on its Abbreviated New Drug Application (ANDA) for preservative-free ketamine. While no major deficiencies were found related to the drug components, the FDA identified a major deficiency concerning the twist-off cap of the product's luer lock vial. Following a clarification meeting, the FDA committed to immediately reinitiate the ANDA review and complete it quickly, acknowledging ketamine's status as a strategic drug on the shortage list. Management views the outcome positively, given the absence of drug-related issues and the FDA's commitment to a swift resolution.
Key Highlights
- NRx Pharmaceuticals filed an ANDA for preservative-free ketamine in September 2025.
- FDA found no major deficiencies related to the drug components in first-round review.
- FDA identified a major deficiency concerning the twist-off cap of the product's luer lock vial.
- Company provided data on 11.9 million doses of similar products shipped without issues.
- A clarification meeting was held on August 6, 2026, with FDA leadership.
- FDA committed to immediately reinitiate ANDA review and complete it in the shortest possible cycle.
- FDA recognized ketamine as a strategic drug on the current FDA drug shortage list.
- Management is optimistic the packaging concern will be resolved for 2026 commercial sales.
Price Impact
More from NRXP